Dubai: December 9, 2020. China para ola Sinopharm experimental coronavirus vaccine toh virus nemite 86% bhal ase koikena Wednesday din United Arab Emirates health ministry para janaishe. Gulf Arab state desh te July moina te Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG) para Phase 3 clinical trials vaccine soruh korishe. September te UAE para emergency samai konuba groups logot joboli junaishe.
Analysis para aro 99% seroconversion rate neutralizing antibody thikaishe aro virus nemite 100% bhal aro kam korishe”, koikena statement te ministry para state news agency logot junaishe. “analysis para eku serious thika nai” koishe. Aro koishe ke, etu vaccine toh officially registered hoishe aro etu oper te UAE trial te 125 desh para 31,000 volunteers khan logot loishe. Hoilebi, khobor toh dosura side effect nohoile keman jun volunteers khan logot vaccine aro placbo thishe janai deya nai. CNBG logot khobor loboli paria nai. UAE laga trial toh Sinopharm’s CNBG, Abu Dhabi-based artificial intelligence company Group 42 (G42) aro Abu Dhabi Department of Health logot melikena korishe. Sinopharm toh G42 toh be Egypt, Jordan aro Bahrain te trials jai ase koishe. UAE laga capital Abu Dhabi, etu hafta koishe, Russia laga COVID-19 vaccine, Sputnik V te clinical trials loboli volunteers khan ke persari ase koishe. UAE te population toh around 9 million thaka oper te coronavirus bemari cases toh 178,837 hoikena ase aro 596 manuh etu bemar para morikena ase koishe.
Add Comment